Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence

Bottom line

• In the pivotal placebo-controlled field study (n=262 evaluable dogs), grapiprant achieved treatment success (CBPI improvement) in 48.1% of dogs vs 31.3% of placebo-treated dogs at day 28.
• Grapiprant is FDA-approved (2016) and EMA-approved (2018) for control of pain and inflammation associated with osteoarthritis in dogs.
• The mechanism is selective EP4 prostaglandin receptor antagonism, blocking PGE2 at the receptor subtype primarily responsible for OA-associated pain and inflammation without broad COX inhibition.
• A 2021 review of the evidence base for grapiprant concluded it has a distinct mechanism from NSAIDs with a potentially favorable GI and renal safety profile compared to non-selective COX inhibitors.
• A 2024 randomized trial comparing grapiprant with meloxicam for postoperative joint pain found both agents provided effective analgesia.

Drug facts

• Class: Piprant (EP4 receptor antagonist; prostaglandin E2 receptor subtype 4 antagonist)
• Mechanism: Selectively blocks the EP4 subtype of prostaglandin E2 receptors, which is primarily responsible for pain sensitization and inflammation in OA; does not directly inhibit COX-1 or COX-2, preserving some prostaglandin-mediated physiologic functions
• Route: Oral tablet
• Indication: FDA-approved for control of pain and inflammation associated with osteoarthritis in dogs; EMA-approved for control of pain associated with osteoarthritis in dogs
• Approval: FDA-approved March 2016 (NADA 141-457) — Elanco; EMA-approved 2018
• Label contraindications: Per label — do not use in dogs younger than 9 months; not for use in breeding, pregnant, or lactating animals; do not co-administer with NSAIDs or corticosteroids (combinatorial GI risk)
• Label common AEs: Per label — vomiting; diarrhea; anorexia; lethargy; soft stools

A specific patient on grapiprant?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=grapiprant-canine-osteoarthritis-pain

What the evidence shows

Pivotal field study: Rausch-Derra et al., 2016

Rausch-Derra et al. conducted a prospective, randomized, masked, placebo-controlled multisite field study enrolling 285 client-owned dogs with confirmed OA across multiple sites, with 262 evaluable (131 per group). Dogs received grapiprant or placebo once daily. Owners completed the Canine Brief Pain Inventory (CBPI) at days 0, 7, 14, 21, and 28; success was defined as improvement in CBPI. Veterinarians completed the Total Orthopaedic Score (TOS).

At day 28, treatment success was 48.1% in the grapiprant group vs 31.3% in the placebo group, with significant improvements in CBPI pain interference scores, pain severity scores, and TOS in favor of grapiprant. The publication (JVIM 2016;30(3):756–763) established the evidentiary basis for FDA approval.

Evidence synthesis: Sartini et al., 2021

A 2021 review published in the Journal of Veterinary Pharmacology and Therapeutics (PMC8518515) synthesized the current knowledge on grapiprant, including pharmacology, efficacy, and safety data. The reviewers noted that EP4 receptor antagonism represents a targeted approach that may spare some COX-mediated prostaglandin functions relevant to GI mucosal integrity and renal perfusion, a potential advantage over non-selective COX inhibitors. The clinical significance of this mechanistic distinction in long-term or high-risk patients continues to be evaluated.

Grapiprant vs meloxicam for postoperative joint pain: 2024 randomized trial

A 2024 randomized, double-blinded, prospective clinical trial (PMC11256200) compared grapiprant and meloxicam for management of postoperative joint pain in dogs. Both agents provided effective analgesia in the postoperative period; the trial contributes to understanding of grapiprant's analgesic profile beyond the OA maintenance indication.

How this fits clinical practice

Grapiprant's EP4-selective mechanism provides an alternative to traditional NSAIDs for canine OA, particularly in patients where non-selective COX inhibition raises GI or renal concerns. The pivotal Rausch-Derra field study demonstrates clinically meaningful — though not dramatic — improvement over placebo at 28 days. Clinicians should set appropriate expectations with clients about the magnitude of benefit.

Grapiprant should not be co-administered with NSAIDs or corticosteroids per the label. Monitoring recommendations for renal and hepatic function should follow current formulary guidance. Dogs with severe OA pain refractory to single-agent management may require multimodal analgesic approaches; consult current WSAVA and IVAPM pain management guidelines.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=grapiprant-canine-osteoarthritis-pain

References

1. Rausch-Derra LC et al. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist, in Dogs with Osteoarthritis. J Vet Intern Med. 2016;30(3):756-763. https://pmc.ncbi.nlm.nih.gov/articles/PMC4913586/
2. Sartini I et al. Grapiprant: A snapshot of the current knowledge. J Vet Pharmacol Ther. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8518515/
3. Biscotto A et al. Comparison of grapiprant and meloxicam for management of postoperative joint pain in dogs: A randomized, double-blinded, prospective clinical trial. Vet Anaesth Analg. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11256200/

Changelog

• 2026-06-06: First published.

Related reads

• Oclacitinib Canine Atopic Dermatitis
• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile
• Frunevetmab (Solensia) for Feline Osteoarthritis: Effectiveness and Real-World Safety